Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.

@article{Krueger2005PatientreportedOO,
  title={Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.},
  author={Gerald G. Krueger and Richard B. Langley and Andrew Y Finlay and Christopher Griffiths and Jacqueline Woolley and Deepa Lalla and Angelika Jahreis},
  journal={The British journal of dermatology},
  year={2005},
  volume={153 6},
  pages={1192-9}
}
BACKGROUND Etanercept, a soluble tumour necrosis factor receptor, lessens the severity of psoriasis as measured by physician-reported clinical outcomes. Equally important is the patient perspective on the effect of etanercept therapy on daily life. OBJECTIVES To assess patient-reported outcomes (PROs) in patients with psoriasis receiving etanercept therapy. METHODS In this multinational, randomized, phase III trial, patients with psoriasis received placebo (n = 193), etanercept 50 mg per… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 48 extracted citations

Similar Papers

Loading similar papers…